CAR T cell therapy in solid tumors: a short review

Summary Chimeric antigen receptor (CAR) T cell therapy has been established in the treatment of hematological malignancies. However, in solid tumors its efficacy remains limited. The aim of this article is to give an overview of the field of cell therapy itself, to introduce the underlying concepts...

Full description

Saved in:
Bibliographic Details
Published in:Memo - Magazine of European medical oncology 2021-06, Vol.14 (2), p.143-149
Main Authors: Umut, Öykü, Gottschlich, Adrian, Endres, Stefan, Kobold, Sebastian
Format: Article
Language:English
Subjects:
Medicine
Medicine & Public Health
Oncology
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c423t-1723fa73f061336bbeed1881038aa9d98bec29d21a55bc40b5b492eaa79748043
cites cdi_FETCH-LOGICAL-c423t-1723fa73f061336bbeed1881038aa9d98bec29d21a55bc40b5b492eaa79748043
container_end_page 149
container_issue 2
container_start_page 143
container_title Memo - Magazine of European medical oncology
container_volume 14
creator Umut, Öykü
Gottschlich, Adrian
Endres, Stefan
Kobold, Sebastian
description Summary Chimeric antigen receptor (CAR) T cell therapy has been established in the treatment of hematological malignancies. However, in solid tumors its efficacy remains limited. The aim of this article is to give an overview of the field of cell therapy itself, to introduce the underlying concepts of CAR T cell-based treatment approaches and to address its limitations in advancing the treatment for solid malignancies.
doi_str_mv 10.1007/s12254-021-00703-7
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8550638</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2597803958</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-1723fa73f061336bbeed1881038aa9d98bec29d21a55bc40b5b492eaa79748043</originalsourceid><addsrcrecordid>eNp9kM9Kw0AQxhdRbK2-gKccvURn_2V3PQil-A8KgtTzskk2bUqarbtJpW_TZ-mTmZoiePE0M8z3fcP8ELrGcIsBxF3AhHAWA8FxNwKNxQkaYpnwmINITn97hgfoIoQlQEJAyHM0oEwIkYAaIjYZv0ez_S6zVRU1C-vNehuVdRRcVeZR066cD_eR2e_Cwvkm8nZT2q9LdFaYKtirYx2hj6fH2eQlnr49v07G0zhjhDYxFoQWRtACEkxpkqbW5lhKDFQao3IlU5sRlRNsOE8zBilPmSLWGKEEk8DoCD30ues2Xdk8s3XjTaXXvlwZv9XOlPrvpi4Xeu42WnIOCZVdwM0xwLvP1oZGr8pweNXU1rVBE66EBKr4QUp6aeZdCN4Wv2cw6ANu3ePWHW79g1uLzkR7U-jE9dx6vXStrzsm_7m-Aa2bggk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2597803958</pqid></control><display><type>article</type><title>CAR T cell therapy in solid tumors: a short review</title><source>Springer Nature</source><creator>Umut, Öykü ; Gottschlich, Adrian ; Endres, Stefan ; Kobold, Sebastian</creator><creatorcontrib>Umut, Öykü ; Gottschlich, Adrian ; Endres, Stefan ; Kobold, Sebastian</creatorcontrib><description>Summary Chimeric antigen receptor (CAR) T cell therapy has been established in the treatment of hematological malignancies. However, in solid tumors its efficacy remains limited. The aim of this article is to give an overview of the field of cell therapy itself, to introduce the underlying concepts of CAR T cell-based treatment approaches and to address its limitations in advancing the treatment for solid malignancies.</description><identifier>ISSN: 1865-5041</identifier><identifier>EISSN: 1865-5076</identifier><identifier>DOI: 10.1007/s12254-021-00703-7</identifier><identifier>PMID: 34777609</identifier><language>eng</language><publisher>Vienna: Springer Vienna</publisher><subject>Medicine ; Medicine &amp; Public Health ; Oncology ; Review</subject><ispartof>Memo - Magazine of European medical oncology, 2021-06, Vol.14 (2), p.143-149</ispartof><rights>The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-1723fa73f061336bbeed1881038aa9d98bec29d21a55bc40b5b492eaa79748043</citedby><cites>FETCH-LOGICAL-c423t-1723fa73f061336bbeed1881038aa9d98bec29d21a55bc40b5b492eaa79748043</cites><orcidid>0000-0002-5612-4673</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids></links><search><creatorcontrib>Umut, Öykü</creatorcontrib><creatorcontrib>Gottschlich, Adrian</creatorcontrib><creatorcontrib>Endres, Stefan</creatorcontrib><creatorcontrib>Kobold, Sebastian</creatorcontrib><title>CAR T cell therapy in solid tumors: a short review</title><title>Memo - Magazine of European medical oncology</title><addtitle>memo</addtitle><description>Summary Chimeric antigen receptor (CAR) T cell therapy has been established in the treatment of hematological malignancies. However, in solid tumors its efficacy remains limited. The aim of this article is to give an overview of the field of cell therapy itself, to introduce the underlying concepts of CAR T cell-based treatment approaches and to address its limitations in advancing the treatment for solid malignancies.</description><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Oncology</subject><subject>Review</subject><issn>1865-5041</issn><issn>1865-5076</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kM9Kw0AQxhdRbK2-gKccvURn_2V3PQil-A8KgtTzskk2bUqarbtJpW_TZ-mTmZoiePE0M8z3fcP8ELrGcIsBxF3AhHAWA8FxNwKNxQkaYpnwmINITn97hgfoIoQlQEJAyHM0oEwIkYAaIjYZv0ez_S6zVRU1C-vNehuVdRRcVeZR066cD_eR2e_Cwvkm8nZT2q9LdFaYKtirYx2hj6fH2eQlnr49v07G0zhjhDYxFoQWRtACEkxpkqbW5lhKDFQao3IlU5sRlRNsOE8zBilPmSLWGKEEk8DoCD30ues2Xdk8s3XjTaXXvlwZv9XOlPrvpi4Xeu42WnIOCZVdwM0xwLvP1oZGr8pweNXU1rVBE66EBKr4QUp6aeZdCN4Wv2cw6ANu3ePWHW79g1uLzkR7U-jE9dx6vXStrzsm_7m-Aa2bggk</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Umut, Öykü</creator><creator>Gottschlich, Adrian</creator><creator>Endres, Stefan</creator><creator>Kobold, Sebastian</creator><general>Springer Vienna</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5612-4673</orcidid></search><sort><creationdate>20210601</creationdate><title>CAR T cell therapy in solid tumors: a short review</title><author>Umut, Öykü ; Gottschlich, Adrian ; Endres, Stefan ; Kobold, Sebastian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-1723fa73f061336bbeed1881038aa9d98bec29d21a55bc40b5b492eaa79748043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Oncology</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Umut, Öykü</creatorcontrib><creatorcontrib>Gottschlich, Adrian</creatorcontrib><creatorcontrib>Endres, Stefan</creatorcontrib><creatorcontrib>Kobold, Sebastian</creatorcontrib><collection>SpringerOpen (Open Access)</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Memo - Magazine of European medical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Umut, Öykü</au><au>Gottschlich, Adrian</au><au>Endres, Stefan</au><au>Kobold, Sebastian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CAR T cell therapy in solid tumors: a short review</atitle><jtitle>Memo - Magazine of European medical oncology</jtitle><stitle>memo</stitle><date>2021-06-01</date><risdate>2021</risdate><volume>14</volume><issue>2</issue><spage>143</spage><epage>149</epage><pages>143-149</pages><issn>1865-5041</issn><eissn>1865-5076</eissn><abstract>Summary Chimeric antigen receptor (CAR) T cell therapy has been established in the treatment of hematological malignancies. However, in solid tumors its efficacy remains limited. The aim of this article is to give an overview of the field of cell therapy itself, to introduce the underlying concepts of CAR T cell-based treatment approaches and to address its limitations in advancing the treatment for solid malignancies.</abstract><cop>Vienna</cop><pub>Springer Vienna</pub><pmid>34777609</pmid><doi>10.1007/s12254-021-00703-7</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-5612-4673</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1865-5041
ispartof Memo - Magazine of European medical oncology, 2021-06, Vol.14 (2), p.143-149
issn 1865-5041
1865-5076
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8550638
source Springer Nature
subjects Medicine
Medicine & Public Health
Oncology
Review
title CAR T cell therapy in solid tumors: a short review
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T02%3A03%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CAR%20T%C2%A0cell%20therapy%20in%20solid%20tumors:%20a%C2%A0short%20review&rft.jtitle=Memo%20-%20Magazine%20of%20European%20medical%20oncology&rft.au=Umut,%20%C3%96yk%C3%BC&rft.date=2021-06-01&rft.volume=14&rft.issue=2&rft.spage=143&rft.epage=149&rft.pages=143-149&rft.issn=1865-5041&rft.eissn=1865-5076&rft_id=info:doi/10.1007/s12254-021-00703-7&rft_dat=%3Cproquest_pubme%3E2597803958%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c423t-1723fa73f061336bbeed1881038aa9d98bec29d21a55bc40b5b492eaa79748043%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2597803958&rft_id=info:pmid/34777609&rfr_iscdi=true